Regional Licensed Products. 14.9.2.1. Each Party has the right to use any Trademark it owns or controls for Regional Licensed Products in its Territory at its sole discretion, and each Party and its Affiliates will retain all right, title and interest in and to its and their respective corporate names and logos.
Regional Licensed Products. 7.2.1. Regulatory Filings and Interactions.
Regional Licensed Products. On a Regional Target-by-Regional Target basis, Novartis will make the following Sales Milestone Payments to Surface upon achievement of the corresponding Sales Milestone Event for all Regional Licensed Products for such Regional Target: Annual Net Sales in the Novartis Territory in a Given Calendar Year for all Regional Licensed Products Sales Milestone Payment [***] [***]
Regional Licensed Products. Novartis will, on a Regional Target-by-Regional Target basis, make the following Developmental Milestone Payments to Surface upon the first achievement of the corresponding Developmental Milestone Event for a Regional Target: Developmental Milestone Event Developmental Milestone Payment [***] [***] CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Regional Licensed Products. 10.9.3.1. Novartis will pay to Surface royalties on a Regional Licensed Product-by-Regional Licensed Product basis on Annual Net Sales for each Regional Licensed Product in the Novartis Territory at the royalty rates (the “Novartis Regional Royalty Rates”) set forth below (the “Novartis Regional Net Sales Royalty”). Annual Net Sales Royalty Rate [***] [***] The applicable Novartis Regional Net Sales Royalty will be calculated by reference to the Annual Net Sales of each Regional Licensed Product in the Novartis Territory. See Exhibit M for an example of such calculation. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Regional Licensed Products. On a Regional Target Pair-by-Regional Target Pair basis, Novartis will make the following Developmental Milestone Payments to Xencor upon the first achievement of the corresponding Developmental Milestone Event for each Regional Target Pair: Developmental Milestone Event Developmental Milestone Payment [...***...] $[...***...] [...***...] $[...***...] [...***...] $[...***...] [...***...] $[...***...] [...***...] $[...***...] [...***...] $[...***...] Total potential Development and Regulatory Milestone Payments per Regional Target Pair $200,000,000
Regional Licensed Products. On a Regional Target Pair-by-Regional Target Pair basis, Novartis will make the following Sales Milestone Payments to Xencor upon achievement of the corresponding Sales Milestone Event for all Regional Licensed Products for such Regional Target Pair in the Novartis Territory: ***Confidential Treatment Requested Annual Net Sales in the Novartis Territory in a Given Calendar Year for all Regional Licensed Products for a Regional Target Pair Sales Milestone Payment $[...***...] $[...***...] $[...***...] $[...***...] $[...***...] $[...***...] Total potential Sales Milestone Payments per Regional Target Pair $125,000,000
Regional Licensed Products. 10.6.1.1. Subject to Section 10.6.1.2, Novartis will pay to Xencor royalties on a Regional Licensed Product-by-Regional Licensed Product basis on Annual Net Sales for each Regional Licensed Product in the Novartis Territory at the royalty rates set forth below. Annual Net Sales Royalty Rate Portion up to and including $[...***...] [...***...]% Portion greater than $[...***...] up to and including $[...***...] [...***...]% Portion greater than $[...***...] [...***...]%
Regional Licensed Products. [...***...] Section 10.6.2
Regional Licensed Products. Novartis will, on a Regional Target-by-Regional Target basis, make the following Developmental Milestone Payments to Surface upon the first achievement of the corresponding Developmental Milestone Event for a Regional Target: Developmental Milestone Event Developmental Milestone Payment [***] [***]
